Clinical Trial: NCT05720130
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | AdvanCell Pty Limited |
| Information Provided By: | AdvanCell Pty Limited |
| Last Update Posted: | 2026-02-20 |
Study Overview
Brief Summary
This is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of [212Pb]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establish the recommended phase 2 doses (RP2D). The Phase 2a expansion aims to assess the efficacy and safety of [212Pb]Pb-ADVC001 at the RP2 doses in 3 participant groups.
Official Title
Conditions
Intervention / Treatment
- Drug: [²¹²Pb]Pb-ADVC001 (Phase 1b)
- Drug: [²¹²Pb]Pb-ADVC001 (Phase 2a)
Other Study ID Numbers
- PSMA-AC-01
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | AdvanCell Pty Limited |
| Information Provided By: | AdvanCell Pty Limited |
| Last Update Posted: | 2026-02-20 |
Study Overview
Brief Summary
This is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of [212Pb]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establish the recommended phase 2 doses (RP2D). The Phase 2a expansion aims to assess the efficacy and safety of [212Pb]Pb-ADVC001 at the RP2 doses in 3 participant groups.
Official Title
Conditions
Intervention / Treatment
- Drug: [²¹²Pb]Pb-ADVC001 (Phase 1b)
- Drug: [²¹²Pb]Pb-ADVC001 (Phase 2a)
Other Study ID Numbers
- PSMA-AC-01